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Abstract
Clostridium difficile, a spore-forming bacterium, causes antibiotic-associated diarrhea. In order to produce toxins and cause
disease, C. difficile spores must germinate and grow out as vegetative cells in the host. Although a few compounds capable
of germinating C. difficile spores in vitro have been identified, the in vivo signal(s) to which the spores respond were not
previously known. Examination of intestinal and cecal extracts from untreated and antibiotic-treated mice revealed that
extracts from the antibiotic-treated mice can stimulate colony formation from spores to greater levels. Treatment of these
extracts with cholestyramine, a bile salt binding resin, severely decreased the ability of the extracts to stimulate colony
formation from spores. This result, along with the facts that the germination factor is small, heat-stable, and water-soluble,
support the idea that bile salts stimulate germination of C. difficile spores in vivo. All extracts able to stimulate high level of
colony formation from spores had a higher proportion of primary to secondary bile salts than extracts that could not. In
addition, cecal flora from antibiotic-treated mice was less able to modify the germinant taurocholate relative to flora from
untreated mice, indicating that the population of bile salt modifying bacteria differed between the two groups. Taken
together, these data suggest that an in vivo-produced compound, likely bile salts, stimulates colony formation from C.
difficile spores and that levels of this compound are influenced by the commensal gastrointestinal flora.
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Introduction
Clostridium difficile is a spore-forming, Gram-positive bacterium
estimated to be responsible for about one-quarter of hospital-
acquired infections [1]. C. difficile causes a watery diarrhea, and
transmission of this pathogen likely occurs through ingestion of C.
difficile spores. C. difficile-associated disease (CDAD) can progress to
intestinal lesions, resulting in pseudomembranous colitis charac-
terized by raised yellow plaques throughout the mucosa of the
colon. Though progression to toxic megacolon, intestinal perfo-
rations, peritonitis, and death is uncommon, it does occur [1,2].
Although C. difficile is an obligate anaerobe when in its vegetative
state, its spores have been estimated to persist on dry, inanimate
surfaces for months [3], contributing to its role as a major
nosocomial pathogen. In fact, C. difficile has been suggested to be
the major infectious cause of diarrhea caused by antibiotic usage in
human adults [2] and is especially a problem in elderly and
immunocompromised patients. Although CDAD has a low
mortality rate, C. difficile infection causes longer hospital stays,
and treatment costs are estimated to be more than $3 billion per
year in the U.S. [4]. The beginning of this century has been
marked by a doubling of the rate of CDAD throughout the United
States [1], and the recent emergence of hypervirulent C. difficile
strains has resulted in higher rates of CDAD-associated morbidity,
mortality, and health care costs [5,6].
Two events usually occur prior to development of CDAD:
administration of antibiotics[7],leading to disruption of commensal
bacteria in the host intestine [8], and infection with C. difficile, likely
via the spore form. Since C. difficile infection manifests in patients
undergoing antibiotic treatment, it is not surprising that C. difficile is
naturally resistant to a number of antibiotics [9]. Treatment has
mainly relied on the antibiotics metronidazole and vancomycin
[1,10], which are unsatisfactory given that they prevent reestab-
lishment of the commensal flora so relapses are common [1], and
failure rates for metronidazole are on the rise [11,12].
TwoimportantaspectsofC. difficile infection are germination of the
spores and how this process is regulated in the intestinal environment.
Despite the fact that C. difficile is likely acquired via ingestion of spores
(as the vegetative form will die in the presence of oxygen), only the
vegetative form produces toxins. Thus, to more fully understand
pathogenesis of C. difficile,a better understandingof spore germination
is needed. In general, bacterial spores germinate in response to the
binding of one or more small molecules, and the small molecules that
can cause germination vary among different species and strains of
bacteria [13]. The signals to which C. difficile responds have not been
well-characterized, but the primary bile salts cholate, taurocholate,
and glycocholate have been shown to stimulate germination in vitro
[14,15,16]. In fact, this effect of bile salts is the basis for a standard
method of titering C. difficile spores by colony formation [16].
However, signals to which C. difficile spores respond in vivo have not
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may inhibit C. difficile growth and downregulate C. difficile virulence
gene expression [17,18,19], it is not known what effects normal
intestinal flora have on C. difficile spore germination. The identifica-
tion of intestinal signals that affect C. difficile spore germination could
lead to the discovery of compounds that inhibit germination and thus
CDAD. Here, we examined colony formation from C. difficile spores
in the presence of cecal and intestinal extracts from untreated and
antibiotic-treated mice as well as the ability of flora from these mice to
modify the primary bile salt taurocholate.
Materials and Methods
Strains and Growth Conditions
C. difficile CD196 [20] was grown in BHI liquid medium (Bacto
brain-heart infusion [BD]) or BHIS plates (BHI supplemented
with yeast extract to 5 mg/ml and L-cysteine to 0.1% [w/v]) at
37uC in a Don Whitley MiniMACS anaerobic chamber (80% N2,
10% H2, 10% CO2). Taurocholic acid (TA) (Sigma) was added to
0.1% where indicated. Spores of CD196 were prepared as
previously described [14].
To construct a strain overexpressing 7a-hydroxysteroid dehy-
drogenase (7a-HSDH), first the hdhA gene (Entrez GeneID 946151),
which encodes 7a-HSDH, was PCR-amplified from the MG1655-
based E. coli strain PK7743 [21] using primers 59-CACTCTCA-
TATGTTTAATTCTGACAACCTGAGAC-39 and 59-TCT-
CGAGTTAATTGAGCTCCTGTACCCCACC-3.9 This DNA
fragment was restriction digested and cloned into the NdeI and
XhoI sites of pET-32a. The resulting plasmid, pJG32, was
transformed into E. coli strain BL21 to give strain JG73.
Antibiotic Treatment and Preparation of Cecal and
Intestinal Extracts
Mouse protocols were approved by the Institutional Animal Care
and Use Committee at the University of Pennsylvania. CD-1
mother mice were given clindamycin hydrochloride (Spectrum
Chemical) or ampicillin (Research Products International) orogas-
trically in two doses each of 200 mg/kg of body weight in a 20 hour
period and were sacrificed 24 hours after the initial antibiotic
treatment. Streptomycin sulfate (Research Products International)
was added to the drinking water to a final concentration of 5 mg/ml
for 24 hours as previously described [22]. Mice were sacrificed by
CO2 asphyxiation and cervical dislocation, and the small intestine,
cecum, and large intestine were harvested. Organs were weighed
and homogenized in 1 ml H2O per mg weight, pelleted, and the
supernatant wasfiltered througha 0.2 mm filter orboiledtosterilize.
Boiling was followed by centrifugation at 16,0006g for 5 min., and
supernatants were frozen at 220uC until use. Extracts were spotted
onto BHIS plates to ensure that no colonies formed from the
extracts in the absence of added spores. Where indicated, extracts
were dialyzed against water in a 1 kDa membrane for 4 hours. For
some experiments, cholestyramine resin (Sigma) was added to a
final concentration of 50 mg/ml to small intestinal or cecal extracts
or to 0.1% taurocholate, rocked for 1 hour at room temperature,
and pelleted by centrifugation. The supernatant from dialysis or
cholestyramine treatment was boiled to sterilize and used in colony
forming unit (CFU) recovery assays as described below.
CFU Recovery Assays
Spores were incubated anaerobically with the indicated extracts
for 30 min. at 37uC, at which point dilutions were made, spread
onto individual BHIS and BHIS + TA plates, and colonies
enumerated after overnight growth. Spores of C. difficile will form
colonies with extremely low efficiency on plated media in the
absence of a germinant such as bile salts [14,16]. CFU recovery is
reported as the CFU/ml on BHIS plates relative to those for
untreated spores spread on BHIS + TA plates.
Determination of Bile Salt Levels
Measuring the production of NADH during the oxidation of the
hydroxyl groups of bile salts by hydroxysteroid dehydrogenases
(HSDHs)can be used as a method to quantify bile salts [23]. Briefly,
the background absorbance at 340 nm for bile salt standards (TA,
deoxycholate [DCA], or chenodeoxycholate [CDCA]) or murine
cecal or intestinal extracts in 900 mM glycine/NaOH buffer,
pH 9.5 and 2.65 mM NAD was measured. Reactions were initiated
by addition of 3a-HSDH (Worthington) at a final concentration of
80 mg/ml, and absorbance at 340 nm was measured until it no
longer increased. Total concentrations of bile salts were calculated
by generating standard curves and solving the equation A340 =
k(CA + DCA + CDCA), where k is the extinction coefficient of
NADH and CA is cholate. Quantitation of bile salts with a hydroxyl
group at the C7 position(i.e., primary bile salts)were performedin a
similar manner, except that supernatant from cells overexpressing
7a-HSDH was used to initiate the reaction and the equation solved
was A340 =k ( C A+ CDCA). This supernatant was prepared as
follows: strain JG73 was grown to mid-log phase, at which time
IPTG was added to a final concentration of 1 mM to induce
overproduction of 7a-HSDH. After a 2 hour induction period, cells
were pelleted and frozen at 220uC. On the day of the assay, the
pellet was resuspended in 0.1 M sodium phosphate, 1 mM EDTA,
pH 7 buffer,sonicated,and centrifugedfor20min.at60006g.The
supernatant was immediately used in HSDH assays.
Incubation of Taurocholate with Small Intestinal and
Cecal Contents
The contents of small intestines and ceca from freshly euthanized
mice treated with or without clindamycin were removed in the
anaerobic chamber and washed five times with PBS to remove any
bilesaltspresent.Pelletswereresuspendedin0.1%TAandincubated
anaerobically for 24 hours at 37uC. Samples were pelleted, and the
supernatant was boiled to sterilize for use in CFU recovery assays.
Results
An Ex Vivo Factor Stimulates Colony Formation from C.
difficile Spores
To examine whether compounds present in the mouse gastroin-
testinaltractcouldstimulategerminationofC.difficilespores,separate
extracts of small intestines, ceca, and large intestines from untreated
adult mice were prepared and used in CFU recovery assays. The
density of the extracts precluded the use of a spectrophotometric
assay for germination [14]. Dormant spores have a very low
efficiency of colony formation on BHIS medium unless the medium
contains an appropriate bile salt; in contrast, germinated spores form
colonies with high efficiency on BHIS medium [14]. Incubation of
sporeswith cecal or large intestinal extractsled to low levelsofcolony
formation, whereas incubation of spores with small intestinal extracts
resultedinabout15% CFUrecovery(Fig.1A).Theseresultsindicate
that there is a factor present in mouse small intestines that can
stimulate germination of C. difficile spores.
Disruption of the Commensal Flora with Antibiotics
Leads to Higher Levels of Colony Formation from C.
difficile Spores
Treatment with clindamycin and ampicillin often precipitate
CDAD in humans [24], and both have been used in animal
C. difficile Germination
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extracts from mice treated with clindamycin, ampicillin, and
streptomycin were also tested for their ability to stimulate colony
formation from C. difficile spores. Cecal extracts from all of the
antibiotic-treated mice showed roughly equal abilities to stimulate
colony formation from C. difficile spores, which was about 502 to
65-fold higher than cecal extracts from the untreated mice (Fig. 1A
and B). The small intestinal extracts from the clindamycin-treated
mice also stimulated high levels of colony formation, but the large
intestinal extract did not.
Since the CFU recovery assay measures not only spore
germination but also outgrowth of the vegetative cells, germination
efficiency was also measured by the loss of heat resistance. Briefly,
spores were incubated with the cecal extracts from untreated or
clindamycin-treated mice for 30 min. at 37u, heat shocked for 20
min. at 60u, then diluted and plated on BHIS + TA plates. Spores
incubated with cecal extract from untreated mice were several-fold
more heat-resistant than were spores incubated with cecal extract
from clindamycin-treated mice (data not shown). Although the
reason for the differences in magnitude between the CFU recovery
assay and the heat shock experiment is unclear, it is unlikely that
outgrowth was inhibited to a great degree in the CFU recovery
assay. In the CFU recovery assay, spores treated with different
extracts showed comparable numbers of colonies on plates
containing TA (data not shown), as can be appreciated in Fig. 1B
(also see Fig. 2). This would not be the case if outgrowth of the
colonies were greatly inhibited. Thus, it appears that the cecal and
intestinal extracts stimulate germination of the spores.
Characterization of the Germination Factor
Several approaches were used to characterize the physical
properties of the factor causing germination of C. difficile spores.
First, to ensure that antibiotics alone did not stimulate spore
germination, spores were incubated with streptomycin at a final
concentration of 200 mg/ml. The CFU recovery from streptomy-
cin-treated spores was comparable to the water control, indicating
that streptomycin alone does not stimulate spore germination (data
not shown). To test the heat stability of the germination factor,
cecal extracts from clindamycin-treated mice were boiled for 10
min.; these extracts showed no difference in CFU recovery
compared to extracts sterilized by passage through a 0.2 mm filter,
indicating that the germination factor is heat-stable and can pass
through a 0.2 mm filter (Fig. 2A). The germination factor appears
to be small, since dialysis of cecal extract from the clindamycin-
treated mice in a membrane with a 1 kDa cutoff abolished its
ability to stimulate CFU recovery from spores (Fig. 2B). Testing
the organic and aqueous fractions from ethyl acetate extraction
indicated that the germination factor goes to the aqueous, not the
Figure 1. An in vivo-produced factor can stimulate CFU recovery from spores of C. difficile.A ) CD196 spores were incubated for 30 min.
with water, 0.1% taurocholate (TA) (gray bar), or extracts from mice that were untreated (black bars) or treated with clindamycin (striped bars),
streptomycin (white bar), or ampicillin (cross-hatched bar), then diluted and spread to BHIS plates. The CFU/ml were compared to the CFU/ml on BHIS
plates containing taurocholate, which was considered to reflect 100% germination. Data are the mean of at least three experiments, with error bars
representing the standard error of the mean. B) Plates from a CFU recovery experiment in which spores were incubated with water, TA, or cecal
extract from untreated or clindamycin-treated mice as in (A), then serially diluted ten-fold and spotted onto BHIS or BHIS + TA plates. A representative
experiment is shown.
doi:10.1371/journal.pone.0008740.g001
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the germination factor is a compound present at higher levels in
vivo in response to antibiotic treatment (but is not itself the added
streptomycin), and is small, heat-stable, and water-soluble.
Treatment of Extracts with Cholestyramine Decreases
Their Ability to Stimulate Colony Formation from C.
difficile Sspores
These physical characteristics and the presence of the factor in
untreated and antibiotic-treated mice (albeit at different locations
along the gastrointestinal tract) are consistent with bile salts as an
in vivo germination factor. Previous in vitro work has shown that
purified primary bile salts such as taurocholate, glycocholate, and
cholate stimulate spore germination [14,16]. As a test of whether
bile salts are an in vivo germination factor, the bile acid
sequestrant cholestyramine was used. Treatment of 0.1%
taurocholate with cholestyramine resin decreased its ability to
germinate spores about 200-fold (Fig. 3). Similarly, cholestyramine
treatment of the cecal and small intestinal extracts from the
clindamycin-treated mice and the small intestinal extracts from the
untreated mice severely decreased their abilities to stimulate
colony formation from C. difficile spores (Fig. 3). Spores that had
been incubated with cholestyramine-treated samples were still able
to germinate on plates containing TA, indicating that the resin
itself did not interfere with germination. Importantly, bile salt
levels in the cholestyramine-treated samples were below the limits
of detection in hydroxysteroid dehydrogenase (HSDH) assays (data
not shown). These results support the idea that the germination
factor may be a bile salt that is present in the small intestines of
untreated mice and in the cecal and small intestinal extracts of
antibiotic-treated mice.
Murine Small Intestinal and Cecal Extracts That Can
Stimulate Colony Formation from Spores Contain Higher
Proportions of Primary Bile Salts
To examine whether bile salts levels differ among small
intestinal and cecal extracts from untreated and clindamycin-
treated mice, HSDH assays were carried out as previously
described [23]. Total bile salt levels in extracts from small
intestines were about 10-fold higher than those from cecal extracts
(Fig. 4), also consistent with the greater ability of small intestinal
extracts to stimulate colony formation from spores. Surprisingly,
the total levels of bile salts in cecal extracts from untreated and
clindamycin-treated mice were similar despite their differing
abilities to stimulate CFU recovery from spores. Because some
bile salts can inhibit spore germination and/or outgrowth [14,27],
additional HSDH assays were performed to quantify primary and
secondary bile salts (Fig. 4). Indeed, extracts that stimulated colony
formation from spores contained higher levels and proportions of
primary bile salts than did an extract that stimulated colony
formation much less (i.e., cecal homogenate from untreated mice).
Treatment of Taurocholate with Small Intestinal and
Cecal Flora Reduces Its Ability to Stimulate Colony
Formation from C. difficile Spores
Several species of commensal bacteria have been shown to
modify primary bile salts to secondary bile salts via 7a-
dehydroxylation in vitro [28]. Secondary bile salts such as
deoxycholate, formed by the deconjugation and dehydroxylation
of primary bile salts by normal anaerobic intestinal bacteria,
inhibit the growth of C. difficile [14,15]. Since antibiotic treatment
disrupts the commensal gastrointestinal flora, there may be
differences in the bile salt modifying ability of bacteria from the
Figure 2. Investigation of properties of the germination factor. Cecal extracts from clindamycin-treated mice were A) boiled for 10 min., B)
dialyzed against H2O in a 1 kDa membrane, or C) extracted with ethyl acetate (EtOAc) and were tested as in Fig. 1.
doi:10.1371/journal.pone.0008740.g002
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versus those untreated. To test this point, cecal contents were
anaerobically isolated from untreated and clindamycin-treated
mice, washed with PBS to remove endogenous bile salts, and
incubated with 0.1% taurocholate under anaerobic conditions for
24 hours at 37u C. The bile salt levels in the supernatant from this
incubation were quantified (Fig. 5A), and the TA that had been
incubated with cecal contents from clindamycin-treated mice had
not been converted to secondary bile salts. In contrast, over 80%
of the bile salts in the supernatant from incubation of TA with
cecal contents from untreated mice were in the secondary form.
Thus, it appears that the populations of bile salt modifying
bacteria differ between untreated and antibiotic-treated mice.
To test its ability to stimulate colony formation from spores,
sterilized supernatant from this incubation was used in CFU
recovery assays (Fig. 5B). Taurocholate that had been incubated
with cecal contents from the clindamycin-treated mice exhibited 22 to 5-fold higher levels of CFU recovery, respectively, than
taurocholate incubated with contents from untreated mice. Thus,
it appears that flora present in the ceca of non-antibiotic-treated
mice can modify taurocholate and decrease its ability to stimulate
colony formation from C. difficile spores.
Discussion
Here, wehave shown that colony formationfrom C. difficilespores
is stimulated by an in vivo-produced factor present in the
gastrointestinal tract, and that this factor appears to be present at
higher levels in mice treated with antibiotics. These results are
consistent with those from a recent paper in which C. difficile spores
germinated in the presence of small intestinal and cecal contents
from mice treatedwitha protonpumpinhibitor[29]. Intriguingly, a
recent study showed that clindamycin treatment of C. difficile-
infected mice appeared to induce a highly contagious ‘‘super-
shedder’’ state, which indicates that antibiotic treatment also
promotes transmission of the spores [30]. This mouse model
appears to be relevant to the human disease since infection of germ-
free mice with C. difficile resulted in large intestinal inflammation
[31]. In addition, the histopathology of antibiotic-treated mice
infected with C. difficile was similar to that of humans with CDAD,
including the presence of pseudomembranous colitis [32].
Figure 3. Cholestyramine treatment of small intestinal and
cecal homogenates decreases their ability to induce spore
germination. CD196 spores were incubated with the indicated
germinant for 30 min, then diluted and spread onto BHIS plates. The
CFU/ml were compared to the CFU/ml on BHIS plates containing
taurocholate (TA), which was considered to reflect 100% germination.
Data are the mean of at least three experiments, with error bars
representing the standard error of the mean. ND, not done.
doi:10.1371/journal.pone.0008740.g003
Figure4. Proportions ofprimary bilesalts in small intestinaland
cecal extracts. Quantitation of bile salts in small intestinal and cecal
extracts from untreated and clindamycin-treated mice was performed as
previously described [23]. Data are reported as the mean percentages of
total bile salts, with levels of primary bile salts (mM) indicated in the bars
and error bars representing the standard error of the mean.
doi:10.1371/journal.pone.0008740.g004
Figure 5. Modification of taurocholate by cecal flora and its ability
to stimulate CFU recovery from spores. Contents of the ceca from
freshly euthanized, clindaymin-treated (striped bars) or untreated (black
bars) mice were isolated under anaerobic conditions, washed 5 times to
remove any bile salts present, and incubated with 0.1% taurocholate for
24 hours at 37u C. Samples were pelleted, and the supernatant was boiled
a n du s e di nA) bile salt quantitation and B) CFU recovery assays. The CFU/
ml were compared to the CFU/ml recovered from spores incubated with
taurocholate, which was considered 100% germination. Data are the mean
of at least three experiments, with error bars representing the standard
error of the mean. (* p,0.05, Student’s t-test).
doi:10.1371/journal.pone.0008740.g005
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based on its physical properties as well as the result that treatment
of extracts with cholestyramine, a bile salt sequestrant, eliminated
their abilities to stimulate colony formation from C. difficile spores.
Bile salts have been shown to have different effects in vitro: some
(taurocholate, cholate, deoxycholate) stimulate germination, some
inhibit germination (chenodeoxycholate), and some inhibit growth
of vegetative cells (deoxycholate, chenodeoxycholate) [14,27]. For
this reason, the ratio of primary to secondary bile salts was
determined, and those extracts that could stimulate colony
formation from C. difficile spores contained higher levels of primary
bile salts than those that could not. It is important to note,
however, that chenodeoxycholate is a primary bile salt and we
were unable to perform the 12a-HSDH assay that would allow for
comparison of the cholate and chenodeoxycholate levels. We
hypothesize that the extracts able to stimulate CFU recovery have
low levels of chenodeoxycholate (that is, that the majority of the
primary bile salts were cholate or its derivatives) because
chenodeoxycholate can inhibit spore germination even in the
presence of cholate and taurocholate [27]. In addition, the HSDH
assays do not detect sulfated bile salts, which are present in the
murine gastrointestinal tract [33], and detect muricholate, whose
effect on germination is unknown, so these reported bile salt levels
may be approximate.
Based on the results presented here, cholestyramine may appear
to be a good candidate for treatment of CDAD. In fact,
cholestyramine (Questran) has been used to treat CDAD in
humans [34] and in the hamster model [25] with mixed results
[35,36]. Its mode of action was initially thought to be via toxin
binding, which has been shown in vitro [37]. Perhaps the limited
efficacy of cholestyramine in treating CDAD is due to the fact that
bile acid synthesis increases 42 to 6-fold upon its ingestion and/or
because ileal absorption of bile salts may outcompete the ability of
cholestyramine to bind them [38]. In addition, cholestyramine can
bind to vancomycin, one of the antibiotics used to treat CDAD
[37].
We also investigated the ability of cecal flora from untreated
and clindamycin-treated mice to modify the bile salt taurocholate.
The results suggest that populations of bile salt modifying bacteria
differ between untreated and antibiotic-treated mice, consistent
with recent reports showing that antibiotic treatment of mice
greatly reduces the diversity of their gastrointestinal flora [30,39].
In addition, taurocholate that had been incubated with cecal
contents from clindamycin-treated mice exhibited higher levels of
CFU recovery than taurocholate incubated with contents from
untreated mice. It is worth noting that the taurocholate that had
been incubated with cecal contents was less able to stimulate
colony formation from C. difficile spores compared to pure 0.1%
taurocholate. Though 7a-dehydroxylation of taurocholate to
deoxycholate may have occurred, the taurocholate also could
have been dehydroxylated at C12 by Bacteroides species [40],
resulting in conversion to chenodeoxycholate, which inhibits spore
germination even when cholate or its derivatives are present, as
mentioned above [27].
Intriguingly, disruption of intestinal bacteria by antibiotic
treatment appears to cause differences in bile salt levels in vivo,
since levels of secondary bile salts in the feces of rats treated with
b-lactam antibiotics decreased while primary bile salt levels
increased [41]. A similar result was observed in humans despite
the bile salt differences between these two species [38]. Stools from
human volunteers treated with neomycin, an aminoglycoside like
streptomycin, exhibited an increase in the primary bile salt cholic
acid compared to the level prior to antibiotic treatment [42] and
showed a decrease in the amount of 7a-dehydroxylation activity
[43], supporting the idea that changes in bile salt levels were due to
a decrease in the commensal flora that carry out 7a-dehydroxyla-
tion of bile salts.
Relationships among Antibiotic Treatment, Commensal
Flora, Bile Salt Metabolism, and Germination of Spores of
C. difficile
A model emerges in which C. difficile spores can be germinated
by primary bile salts such as cholate and its derivatives in the small
intestine and cecum. In healthy humans, CDAD may be avoided
because spore germination can be inhibited by the primary bile
salt chenodeoxycholate [27]. For those C. difficile spores that
manage to germinate in response to cholate and its conjugates,
outgrowth of the vegetative cells would be inhibited by the
secondary bile salt deoxycholate in the large intestine, where bile
salts are present in millimolar ranges [28], concentrations at which
they can inhibit growth in vitro [14]. In contrast, when the host is
treated with antibiotics, C. difficile spores are able to exploit the
accompanying changes in bile salt levels. Antibiotic treatment
disrupts the normal flora that carry out the 7a-dehydroxylation of
bile salts, leaving a larger pool of primary bile salts such as cholate
and its derivatives that can germinate the spores. There is likely
also an unknown mechanism by which levels of chenodeoxycho-
late, a primary bile salt that inhibits spore germination and
outgrowth, are concominantly lowered. Once C. difficile spores
have germinated, the vegetative cells must be able grow out in
order to produce toxins and lead to CDAD. In fact, the CFU/ml
and toxin B levels from C. difficile strains grown in vitro in cecal
contents from clindamycin- or ampicillin-treated mice were about
10,000-fold higher after 24 hours relative to those grown in cecal
contents from non-antibiotic-treated mice [19,44]. This indicates
that treatment of the host with antibiotics creates a favorable
environment for growth of and toxin production by C. difficile
vegetative cells, which would lead to CDAD. The model presented
here suggests that perhaps non-hepatotoxic analogs of cheno-
deoxycholic acid could be administered as a preventative measure
to hospital patients at risk for infection with C. difficile or that those
with the infection could be treated with antibiotic-resistant
probiotics exhibiting 7a- and/or 12a-dehydroxylating activity.
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